Phase IIb trial of ATL 1102 in patients with multiple sclerosis
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2014
At a glance
- Drugs ATL 1102 (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Antisense Therapeutics
- 24 Oct 2014 According to Antisense Therapeutics media release, US FDA has responded affirmatively to the Company plan to submit a U.S. Investigational New Drug (IND) application for initiation of this phase II trial.
- 19 Aug 2014 Antisense Therapeutics has submitted a formal request for the US FDA's assessment of ANP's plans for a Phase IIb trial of ATL1102 in MS patients.
- 19 Mar 2013 Planned initiation date changed to 1 Jan 2014, based on information in an Antisense Therapeutics media release.